Protocol 20-043-NCP. A clinical trial evaluating the Natera SIGNATERA personalized molecular residual disease test for patients with advanced/unresectable non-small cell lung cancer, colorectal cancer, or melanoma planning to receive treatment with a PD-1, PD-L1, or CTLA-4 targeting immune checkpoint inhibitor without concomitant chemotherapy.
SIGNATERA is a blood test that measures circulating tumor DNA (ctDNA) to evaluate patient response/progression based on changes in ctDNA quantity.
The primary objective of the study is to, "examine the impact of SIGNATERA on clinical decision-making regarding continuation, discontinuation, escalation, or de-escalation of immunotherapy along with standard clinical assessment and care."
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.